Latest Investigation News

Nordic Resources has punched a new high-grade gold assay record at its Kopsa project in Finland, confirming a significant northern extension to the deposit. Early 2026 drilling reveals grades far surpassing previous intersections, setting the stage for a resource update later this year.

Neurizon Therapeutics has dosed over 50% of participants in the HEALEY ALS Platform Trial's Regimen I, exceeding recruitment expectations after expanding the cohort from 160 to 240 patients. The accelerated pace puts the company on track for last patient dosing in Q2 2027 and topline results by early Q3 2027.

Neometals has completed a second phase of metallurgical testing at its Ironclad gold deposit, delivering gold recoveries that surpass previous assumptions and support near-term project development.

Mount Hope Mining (ASX:MHM) has completed two drilling phases at its Mt Solitary gold project in NSW’s Cobar Basin, delivering significant high-grade gold intercepts and preparing to launch an expanded Phase 3 drilling campaign targeting resource growth.

Leeuwin Metals has inked a non-binding MOU with Bain Global Resources and MEGA Resources to explore development, funding, and operational pathways for its 342,300oz Marda Gold Project in WA.

MRG Metals has reported strong initial assay results from 32 auger holes at its Fotinho Rare Earth Project in Mozambique, confirming a significant alluvial heavy mineral presence that complements prior findings at the adjacent Adriano project.

Argenica has completed the last FDA-mandated cardiac safety assay for its stroke drug ARG-007, paving the way to lift the clinical hold and initiate Phase 2b trials in the US.

Ark Mines has produced high-grade monazite and titanium dioxide products from its Sandy Mitchell heavy mineral concentrate, marking a key step toward commercialising its North Queensland rare earths project.

Cannindah Resources continues to push the boundaries of its Cannindah Breccia copper-gold deposit with new drilling extending the Southern Shoot and revealing wider, higher-grade zones in both Southern and Northern Shoots, setting the stage for a significant resource upgrade later this year.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

Resonance Health is progressing its MRI Liver Fibrosis device through late-stage clinical validation, targeting FDA biomarker qualification, while maintaining a profitable SaaMD platform and forecasting $16 million revenue for FY26.

Stelar Metals has wrapped up its initial fieldwork at the Hill of Leaders Tungsten Project, setting the stage for drilling campaigns later this year and marking a significant step in exploring a largely untouched mineralised system in the Northern Territory.